Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer releases phase III results for bosutinib

Pfizer releases phase III results for bosutinib

7th December 2010

Pfizer has revealed that a phase III study of the investigational compound bosutinib for chronic myeloid leukaemia (CML) reached a secondary endpoint.

The trial found that 39 percent of patients with newly-diagnosed CML experienced a major molecular response when receiving bosutinib after one year, in comparison to 26 percent of patients treated with imatinib.

However, the study did not achieve its primary endpoint of superior complete cytogenetic response rate at one year versus imatinib in the intent-to-treat population.

The global trial involved the participation of 502 adult patients, who were randomised to receive either bosutinib or imatinib.

Dr Carlo Gambacorti-Passerini, one of the lead investigators and director of an Italian clinical research unit, said he was "encouraged" by the data.

"Based on my experience with bosutinib, I feel it would be an important option for patients with CML," he commented.

CML is one of the four main types of leukaemia and accounts for 15 percent of all cases worldwide.

According to Macmillan Cancer Support, about 700 people in the UK are diagnosed with CML each year. ADNFCR-8000103-ID-800276055-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.